Harrow, Inc. · NASDAQ:HROW
Harrow — Harrow Health — Investor Presentation (September 2019)
19 slides from Harrow's investor presentation, Sep 12, 2019
Slide 1: Harrow September 2019
HARROW NASDAQ: HROW SEPTEMBER 2019
Slide 2: Safe Harbor
HARROW SAFE HARBOR This presentation contains express “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying
Slide 3: Topics Covered
HARROW TOPICS COVERED Introduction to Harrow Health, Inc. Financial Metrics Harrow Health Equity Interests « ImprimisRx Operating Business « Other Subsidiaries ¢ Passive Equity Holdings Defining Success in 2021
Slide 4: Harrow Health Introduction
Harrow Health Introduction ¢ We found pharmaceutical companies. *- We own large equity stakes in these companies. * We own royalties on many of the drug candidates they develop. HARROW a»
Slide 5: Harrow Health Introduction
Harrow Health Introduction HARROW HEALTH INC. He eee Deconsolidated Royalty Opportunities} imprimis ; : IMpriMIs p. elon 50% Surface’'s SURF-100 Surface’s SURF-200, 201 MAYFIELD a Surface’s SURF-300, 301 surface yp = . G Melt’s MELT-100** RA § pha Mayfield’s MAY-88 MELT Radley’s RAD-100, 101 Radley’
Slide 6: Financial Metrics
FINANCIAL METRICS HARROW
Slide 7: Consolidated Financials
Consolidated Financials Revenue Growth: Consolidated Revenues, Assets, and Gross Margins + Q2 2019 Revenue $13.5M 8 + $100M rev run rate goal in 2021 $70,000 (Revenue and Assets in thousands) —_ + 187% ophthalmology rev CAGR 2014-2018 7 + 46% ophthalmology year-over-year $60,000 60% revenue growth (
Slide 8: Equity Interests
HARROW EQUITY INTERESTS IMprimis p surface MELT
Slide 9: ImprimisRx Subsidiary
ImprimisRx Subsidiary WHAT IS IT? . Founded by Harrow in 2014 . 100% owned by Harrow . Leading U.S. ophthalmology pharmaceutical compounder . 100% cash pay business model . Two facilities (30,000 ft?) producing ~30 SKUs . IP focused; 60+ patents filed . 3,000+ physician customers in all 50 states .
Slide 10: Imprimis Deconstructing the Value Chain
Imprimis DECONSTRUCTING THE VALUE CHAIN 7886) a ELE] 100% Affordable Cash Pay Eliminates: Insurance Companies and the dreaded “Prior Authorization” Pharmacy Benefit Managers (PBM) Wholesalers, Distributors Coupons, Discounts, Rebates
Slide 11: Other Subsidiaries: Mayfield and Radley
MANEIELD Women’s health-focused business Drug candidate pipeline: MAY-44 for Dyspareunia symptoms MAY-66 for Recurrent Bacterial Vaginosis MAY-88 for Interstitial Cystitis Aggregate potential addressable market in U.S. of $3B Progress PIND meeting in June 2019; condensed FDA approval pathway for MAY
Slide 12: Harrow Health: Deconsolidated businesses and royalty opportunities
HARROW HEALTH INC. Deconsolidated businesses Royalty opportunities imprimis Re elon Surface’s SURF-100 Surface’s SURF-200, 201 MAY. FIELD bi Surface’s SURF-300, 301 Melt’s MELT-100** § RADLEY* Mayfield’s MAY-88 oat ae Radley’s RAD-100, 101 Radley’s RAD-200 Radley’s RAD-300 * Pursuing a deconsolidati
Slide 13: Passive Equity Holdings: Eton
Passive Equity Holdings HARROW’S DECONSOLIDATED EQUITY PORTFOLIO ESTIMATED VALUE: $47M* @urtace MELT y Eton + Eton was formed by Harrow in 2017 7 Melt $18,375,000 f $17,500,000 3.5M shares at $5.25 + Eton has: 3.5M shares at $5 * 11 drug candidates in pipeline + 7 NDAs submitted or expected to be su
Slide 14: Passive Equity Holdings: Surface
Passive Equity Holdings HARROW’S DECONSOLIDATED EQUITY PORTFOLIO ESTIMATED VALUE: $47M* y Eton y Melt $18,375,000 y $17,500,000 3.5M shares at $5.25 3.5M shares at $5 Surface $11,550,000 3.5M shares at $3.30 HARROW of Sep. 5, 2019, @urtace MELT Surface was formed by Harrow in 2018 Surface is: * Deve
Slide 15: Passive Equity Holdings: Melt
Passive Equity Holdings HARROW’S DECONSOLIDATED EQUITY PORTFOLIO ESTIMATED VALUE: $47M* _ Fic G@urtace MELT y Eton + Melt was formed by Harrow in 2018 y Melt $18,375,000 / $17,500,000 3.5M shares at $5.25 + Melt is: * Developing non-opioid, non-lV, sedation and analgesia drug candidates * MELT-100 f
Slide 16: Defining Success in 2021
DEFINING SUCCESS IN 2021 HARROW
Slide 17: Defining Success in 2021
Defining Success in 2021 Public company objectives: * Drive substantial market capitalization and enterprise value growth * Grow capital base to further operational strategic objectives and shareholders’ returns Operational objectives: * Continue to found, fund and deconsolidate new pharmaceutical b
Slide 18: Company Profile
Company Profile“ TRADING SYMBOL PRICE PER SHARE: AVG. DAILY Q2-2019 TRADING VOLUME NASDAQ: HROW $5.74 264,000 SHARES OUTSTANDING COMMON STOCK: MARKET CAP: STRONG CEO/CFO INCENTIVE THRU 25.2M SHARES $145 MILLION AGrie ve $841 SHARE PHICE. LS |HARROW sets d As of Sep. 5, 2019 a»
Slide 19: Harrow contact details
HARROW 102 Woodmont Blvd. Ste 610 Nashville, Tennessee 37205 (858) 704-4040 IR@HARROWINC.COM WWW.HARROWINC.COM
Harrow Health — Investor Presentation (September 2019) on 6ix